PVX-410

N/A

Report date: 2022/10/26 21:54:57

Base Information

Drug NamePVX-410

Drug Alias NameXBP1US/XBP1SP/CD138/CS1 multipeptide vaccinePVX-410 (composed of 4, 9-mer chemically synthesized peptides from unique regions of 3 MM-associated antigens, X-box binding protein 1 (XBP1), syndecan-1 (CD138), and CS1)PVX-410

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSmoldering Multiple MyelomaTriple Negative Breast NeoplasmsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesDana-Farber Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesOncopep Inc

Inactive CompaniesUniversity of Nebraska

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsSmoldering Multiple MyelomaMultiple Myeloma

Other Information

ATC CodeN/A